Today, 8 PDPs launched a call for sustained EU funding for EDCTP — supporting 20+ years of Europe–Africa clinical research, capacity strengthening, and innovation for global health security. Learn more: www.euvaccine.eu/post/evi-joi...

Last week, the RespiriTB consortium shared some of its most significant results: 🔬 First-in-human PK & safety data for bedaquiline long-acting injectable 🧬 CryoEM structures of cytochrome bc₁:aa₃ inhibitors 💊 MenG inhibitors resensitising bedaquiline-resistant M. tuberculosis 1/2

🎙️ Meet our speakers on June 23: Dr. Clara Aguilar Pérez, Senior Principal Scientist at Johnson & Johnson, has specialized in preclinical in vivo models, clinical microbiology, and cross-functional collaborations supporting drug development and regulatory interactions. #AMR #webinar

🎙️ Meet our speakers: Vivian Cox will speak at the RespiriTB Stakeholder Webinar on 23 June and present interim results from J&J's ongoing Phase 1 study of a bedaquiline long-acting injectable that could transform TB preventive treatment by replacing months of daily pills with a single injection.

𝗗𝗲𝗰𝗼𝗱𝗶𝗻𝗴 𝗜𝗺𝗺𝘂𝗻𝗲 𝗗𝘆𝘀𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 In this study published by researchers from the RespiriNTM project explored how immune signaling pathways and cellular responses become dysregulated in disease, shaping inflammation and clinical outcomes. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

𝗔𝗳𝘁𝗲𝗿 𝘆𝗲𝗮𝗿𝘀 𝗼𝗳 𝘄𝗼𝗿𝗸, 𝘁𝗵𝗲 𝗥𝗲𝘀𝗽𝗶𝗿𝗶𝗧𝗕 𝗰𝗼𝗻𝘀𝗼𝗿𝘁𝗶𝘂𝗺 𝗶𝘀 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝘄𝗵𝗮𝘁 𝗶𝘁 𝗳𝗼𝘂𝗻𝗱 — 𝗮𝗻𝗱 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝗮 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗶𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗳𝘂𝘁𝘂𝗿𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗼𝗻 𝗔𝗠𝗥. On 23 June 2026, 3:30-5 pm, we're hosting a free stakeholder webinar open to everyone. Register now: forms.cloud.microsoft/e/dMq37JFx9z

𝗔𝗳𝘁𝗲𝗿 𝘆𝗲𝗮𝗿𝘀 𝗼𝗳 𝘄𝗼𝗿𝗸, 𝘁𝗵𝗲 𝗥𝗲𝘀𝗽𝗶𝗿𝗶𝗧𝗕 𝗰𝗼𝗻𝘀𝗼𝗿𝘁𝗶𝘂𝗺 𝗶𝘀 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝘄𝗵𝗮𝘁 𝗶𝘁 𝗳𝗼𝘂𝗻𝗱 — 𝗮𝗻𝗱 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝗮 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗶𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗳𝘂𝘁𝘂𝗿𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗼𝗻 𝗔𝗠𝗥. On 23 June 2026, 3:30-5 pm, we're hosting a free stakeholder webinar open to everyone. Register now: forms.cloud.microsoft/e/dMq37JFx9z

✨ We're excited to introduce Linda De Vooght — postdoctoral researcher at the RespiriTB project and the newest face in our AMR Accelerator researcher spotlight series! "Antibiotics should not be taken for granted. People are already dying from infections that are difficult or impossible to treat."

✨ We're excited to introduce Linda De Vooght — postdoctoral researcher at the RespiriTB project and the newest face in our AMR Accelerator researcher spotlight series! "Antibiotics should not be taken for granted. People are already dying from infections that are difficult or impossible to treat."

📢 𝙅𝙪𝙨𝙩 𝙥𝙪𝙗𝙡𝙞𝙨𝙝𝙚𝙙! 𝗧𝗼𝘄𝗮𝗿𝗱𝘀 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗩𝗮𝗰𝗰𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗖. 𝗱𝗶𝗳𝗳𝗶𝗰𝗶𝗹𝗲 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 Today we highlight a study by researchers from the COMBINE project published in Scientific Reports analysing data from over 1,000 participants across Phase II and III clinical trials of 𝘊𝘭𝘰𝘴𝘵𝘳𝘪𝘥𝘪𝘰𝘪𝘥𝘦𝘴 𝘥𝘪𝘧𝘧𝘪𝘤𝘪𝘭𝘦 vaccines.

𝗥𝗲𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗧𝗕 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗶𝗻 𝗛𝗶𝗴𝗵-𝗕𝘂𝗿𝗱𝗲𝗻 𝗦𝗲𝘁𝘁𝗶𝗻𝗴𝘀 Today we highlight a study by researchers of UNITE4TB published in Breathe examining the implementation of molecular diagnostic tools for tuberculosis in resource-limited, high-burden countries. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

✨ Meet Maya Rima, early-career researcher in the RespiriNTM project and the latest voice in our AMR Accelerator researcher spotlight series! We are grateful to Maya for sharing her journey, her insights, and her passion. Find the the link to her interview in the first comment 👇

Our annual Cross Project Meeting of the IMI AMR Accelerator took place on 5 March at BioVersys AG in Basel — and it was a very productive one! Representatives from all projects came together to present progress & discuss the plans ahead. It was great to see the breadth of work across the portfolio.

🫱🏼‍🫲🏻 We're proud to present the #PrIMAVeRaProject and our #perpetualobervationalstudies at the 7th @amr-accelerator.bsky.social Cross-Project Meeting held in Basel yesterday. We look forward to seeing everyone again at the PrIMAVeRa stakeholder meeting at #ESCMID2026! @elskesieswerda.bsky.social

We’re live at the AMR Conference in Basel — come meet us today! 📍 Machine Learning for Gram-negative Permeability (Frederik Deroose) 📍 Improving Translational Pneumonia Models (Carina Vingsbo-Lundberg) 💬 Stop by the posters, say hello, and explore collaboration opportunities.

📢 Call for Data: Help Advance Antibiotic Discovery Against Gram-Negative Bacteria! The AMR Accelerator Scientific Interest Group on Machine Learning is building a predictive model for membrane permeability in Gram-negative bacteria — and we need your support. Link to the survey in first comment 👇

Meet us at the AMR Conference in Basel today and tomorrow! 🧠 Researchers from different projects of the accelerator are presenting posters on Machine Learning for Gram-negative permeability 🧪 Advancing TB drug development with HFS-TB 🫁 The COMBINE Pneumonia Model Will you be there? Get connected!

𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗧𝗕 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 Today we highlight a study published by ERA4TB. It contributes to a growing pipeline of compounds designed to tackle drug-resistant TB through novel mechanisms and strategies. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

𝗥𝗲𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝗧𝗕 𝗣𝗵𝘆𝘀𝗶𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆 A study published by members of our project ERA4TB uncovers how 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 forms tightly biofilm-like cords that dramatically alter its interaction with the immune system. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇 #amr #tuberculosis #antibiotics

𝗥𝗲𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝗧𝗕 𝗣𝗵𝘆𝘀𝗶𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆 A study published by members of our project ERA4TB uncovers how 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 forms tightly biofilm-like cords that dramatically alter its interaction with the immune system. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇 #amr #tuberculosis #antibiotics

Hear from Marie Attwood (@reepkpd333.bsky.social) in an exclusive interview about her work in using 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 models in AMR research as a GNA NOW PK/PD expert. She offers insights into: 🔬 Decade of progression 🧫 Hollow-fibre modelling 🦠 AI-driven discovery 🔗 https://bit.ly/4plTnqW

We are excited to share the latest work under RespiriTB, published in Nature Communications! The study explores how targeting the M. tuberculosis cytochrome bc1 complex could unlock new treatment options for both DS-TB & MDR-TB. 👉 https://go.nature.com/48cWgEV

How can we speed up TB clinical trials efficiently? Our latest work led by global TB experts, under UNITE4TB defines the ideal biomarker assays to reliably track treatment response, therefore helping trials be faster, smarter and more effective. 👉 Read at: https://bit.ly/4iVmPAu

𝗨𝗻𝗺𝗮𝘀𝗸𝗶𝗻𝗴 𝗛𝗼𝘀𝘁–𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗧𝗕 Today we showcase a study by our project ERA4TB revealing a previously underappreciated mechanism by which 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 aggregates kill macrophages without being taken up by them. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

𝗨𝗻𝗺𝗮𝘀𝗸𝗶𝗻𝗴 𝗛𝗼𝘀𝘁–𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗧𝗕 Today we showcase a study by our project ERA4TB revealing a previously underappreciated mechanism by which 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 aggregates kill macrophages without being taken up by them. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

♀️ Today is the #InternationalDayofWomenandGirlsinScience! 🧠 Meet Ariane Bollack, a former PhD student from the AMYPAD project who's now working in industry. We asked her how the PPP shaped her career & what advice she has for young researchers 👉 link.europa.eu/K6GPPp #WomenInScience #WomenInSTEM

In this latest study under @era4tb.bsky.social, researchers adopted physiologically‑based pharmacokinetic (PBPK) modelling and used a detailed computational model to project what those concentrations likely are in human lungs (both healthy and TB-infected). 👉 Read at: https://bit.ly/3KA2RQx

Hear from Pedro Quintela in an interview about his work in GNA NOW advancing 𝘪𝘯 𝘷𝘪𝘷𝘰 proof-of-concept models for AMR research. He shares insights into: 🦠 Broader pathogen coverage 🤝 Interdisciplinary collaboration 💡 Championing the promise of each experiment https://bit.ly/49Hdtr1

𝗧𝗵𝗲 𝗖𝗢𝗠𝗕𝗜𝗡𝗘 𝗣𝗻𝗲𝘂𝗺𝗼𝗻𝗶𝗮 𝗠𝗼𝗱𝗲𝗹: 𝗡𝗲𝘄 𝘁𝗼𝗼𝗹𝘀 𝗳𝗼𝗿 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗱𝗿𝘂𝗴-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗽𝗻𝗲𝘂𝗺𝗼𝗻𝗶𝗮 𝗡𝗼𝘄 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗦𝗽𝗲𝗰𝘁𝗿𝘂𝗺, this framework is openly available to academia, CROs, and industry. A real enabler for accelerating antibiotics against WHO-listed critical pathogens. #AMR

🚨 The AMR Accelerator needs your help! Our Machine Learning group seeks datasets to build a Gram-negative permeability prediction model. 𝗜𝗳 𝘆𝗼𝘂 𝗵𝗮𝘃𝗲 𝘀𝘂𝗶𝘁𝗮𝗯𝗹𝗲 𝗱𝗮𝘁𝗮𝘀𝗲𝘁𝘀, 𝗽𝗹𝗲𝗮𝘀𝗲 𝘃𝗶𝘀𝗶𝘁: https://bit.ly/4piUvMw Fill out a form and we will contact you!